Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Company Profile


7000 Shoreline Court

South San Francisco, CA 94080


Industry: Biotechnology

Sector: Healthcare


Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds that target infections caused by acinetobacter baumannii and pseudomonas aeruginosa; and therapeutic antibody discovery program. The company has development services agreement with ARK Diagnostics, Inc. to co-develop an in vitro assay to measure levels of plazomicin in the blood to enable patients to receive safe and efficacious doses of plazomicin; and license agreement with Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds. Achaogen, Inc. also has a collaboration and license agreement with Crystal Bioscience, Inc. to discover unique monoclonal antibodies against various targets. The company was incorporated in 2002 and is headquartered in South San Francisco, California.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank